Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

  • STATUS
    Recruiting
  • End date
    Dec 31, 2025
  • participants needed
    250
  • sponsor
    Oslo University Hospital
Updated on 19 February 2024
cancer
adenocarcinoma
pancreatic adenocarcinoma
folfirinox
surgical exploration
pancreatic cancer

Summary

This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based cohort. Eligible patients are treated with neoadjuvant chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up.

Details
Condition Pancreatectomy, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Age 18-100 years
Treatment FOLFIRINOX
Clinical Study IdentifierNCT04423731
SponsorOslo University Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2015)
Nx, M0 (UICC 8 th version, 2016)
cytological or histological confirmation of adenocarcinoma
age > 18 year and considered fit for major surgery
written informed consent
considered able to receive the study-specific chemotherapy

Exclusion Criteria

co-morbidity precluding pancreatectomy
chronic neuropathy grade 2
WHO performance score > 2
granulocyte count < 1500 per cubic millimetre
platelet count < 100 000 per cubic millimetre
serum creatinine > 1.5 UNL (upper limit normal range)
albumin < 2,5 g/dl
female patients in child-bearing age not using adequate contraception, pregnant or lactating women
mental or physical disorders that could interfere with treatment of with the provision of informed consent
any reason why, in the opinion of the investigator, the patient should not participate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.